Liminatus Pharma, Inc. (LIMN)
↓ Download CSV| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Income | -$2.97M | -$3.33M | — |
| Net Income | -$10.21M | -$3.55M | — |
| EPS (Diluted) | $-0.43 | $-0.20 | — |
| Total Assets | $512.8K | $5.41M | — |
| Total Liabilities | $10.33M | $24.75M | — |
| Shareholders' Equity | -$9.81M | -$19.34M | -$15.79M |
| Operating Cash Flow | -$9.96M | -$1.45M | — |
| Capital Expenditures | $13.1K | — | — |
| Shares Outstanding | 27.06M | 17.50M | — |